Resources Repository
-
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | Government/Law | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | North America -
ArticlePublication 2020Valuing COVID-19 Mortality Risk
In this article, the author evaluates whether conventional estimates of the value per statistical life …
In this article, the author evaluates whether conventional estimates of the value per statistical life (VSL) in the United States (about $10 million) are appropriate for evaluating policies that affect risk of COVID-19. This estimate may be too large, because: (1) VSL estimates marginal values but COVID-19 risks can be non-marginal; (2) VSL is estimated for the average resident, but COVID-19 mortality is concentrated among the elderly; and (3) the pandemic has caused substantial losses…
Preferences/Values | Government/Law | Benefit-Cost Analysis | Infectious Diseases | Global -
ArticlePublication 2021COVID and the Age–VSL Relationship
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions …
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions in analyses of lockdowns and other policies. Many rely on a population-average estimate of the value per statistical life (VSL); others adjust VSL for life expectancy at the age of death. The article explores the implications of theory and empirical studies, which suggest that the relationship between age and VSL is uncertain; these uncertainties in turn may affect whether the…
Preferences/Values | Government/Law | Benefit-Cost Analysis | Infectious Diseases | Health/Medicine | North America -
ArticlePublication 2018Motivational Interviewing: A Promising Tool to Address Vaccine Hesitancy
In most countries, there is an increase in ‘‘vaccine hesitancy,” defined as the proportion of …
In most countries, there is an increase in ‘‘vaccine hesitancy,” defined as the proportion of parents who refuse some, many, or all vaccines or who adopt a delayed vaccination schedule, regardless of the availability of vaccination services. Generally, approaches to address vaccine hesitancy suggest either strong policies of mandatory immunization or more traditional approaches of education and information. Although mandatory immunization policies may increase uptake of vaccines, they do not address the root causes of…
Preferences/Values | Government/Law | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology | North America -
ArticlePublication 2021Anti-Vaccination Infodemic on Social Media: A Behavioral Analysis
Vaccinations are without doubt one of the greatest achievements of modern medicine, and there is …
Vaccinations are without doubt one of the greatest achievements of modern medicine, and there is hope that they can constitute a solution to halt the ongoing COVID-19 pandemic. However, the anti-vaccination movement is currently on the rise, spreading online misinformation about vaccine safety and causing a worrying reduction in vaccination rates worldwide. In this historical time, it is imperative to understand the reasons of vaccine hesitancy, and to find effective strategies to dismantle the rhetoric…
Preferences/Values | Government/Law | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology | North America -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Costing Methods | Government/Law | Health Outcomes | Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Global -
ReportPublication 2016Economics of Tobacco and Tobacco Control
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco …
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco use, tobacco growing, manufacturing and trade, tobacco product taxes and prices, and tobacco control policies and other interventions to reduce tobacco use and its consequences. The report was co-produced by the National Cancer Institute and the World Health Organization and is intended to inform tobacco prevention and control programs and policies in countries around the world. There are 17 chapters which can be…
Costing Methods | Government/Law | Benefit-Cost Analysis | Chronic Disease/Risk | Policy/Regulation | Food/Agriculture | Health/Medicine | Global -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Costing Methods | Government/Law | Benefit-Cost Analysis | Chronic Disease/Risk | Policy/Regulation | Health/Medicine | North America -
ArticlePublication 2017Making Fair Choices on the Path to UHC: Applying Principles to Difficult Cases
Progress toward universal health coverage (UHC) requires making difficult trade-offs. The World Health Organization (WHO) …
Progress toward universal health coverage (UHC) requires making difficult trade-offs. The World Health Organization (WHO) Consultative Group on Equity and UHC has endorsed the principles for making such decisions. These principles include maximizing population health, priority for the worse off, and shielding people from health-related financial risks. But how should one apply these principles in particular cases, and how should one adjudicate between them when their demands conflict? This article by some members of the…
Priority Setting/Ethics | Government/Law | Health Systems | Policy/Regulation | Culture/Society | Economics/Finance | Health/Medicine | Global